Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. So on that note, AlzChem Group (ETR:ACT) looks quite promising in regards to its trends of return on capital.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Return On Capital Employed (ROCE): What Is It?

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. Analysts use this formula to calculate it for AlzChem Group:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.18 = €77m ÷ (€557m - €118m) (Based on the trailing twelve months to March 2025).

So, AlzChem Group has an ROCE of 18%. In absolute terms, that's a satisfactory return, but compared to the Chemicals industry average of 6.2% it's much better.

See our latest analysis for AlzChem Group

In the above chart we have measured AlzChem Group's prior ROCE against its prior performance, but the future is arguably more important. If you'd like, you can check out the forecasts from the analysts covering AlzChem Group for free.

What Can We Tell From AlzChem Group's ROCE Trend?

Investors would be pleased with what's happening at AlzChem Group. Over the last five years, returns on capital employed have risen substantially to 18%. The amount of capital employed has increased too, by 58%. So we're very much inspired by what we're seeing at AlzChem Group thanks to its ability to profitably reinvest capital.

The Bottom Line On AlzChem Group's ROCE

To sum it up, AlzChem Group has proven it can reinvest in the business and generate higher returns on that capital employed, which is terrific. And with the stock having performed exceptionally well over the last five years, these patterns are being accounted for by investors. With that being said, we still think the promising fundamentals mean the company deserves some further due diligence.

While AlzChem Group looks impressive, no company is worth an infinite price. The intrinsic value infographic for ACT helps visualize whether it is currently trading for a fair price.

For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.